Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 4/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 3/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3183551 | 1.00 | GRIK1 (0.43) | GRIK1GRIA2NAAAGRM2GRM3 | |
| SCHEMBL6275628 | 1.00 | GRIK1 (0.43) | GRIK1GRIA2NAAAGRM2GRM3 | |
| SCHEMBL1006306 | 0.87 | CTSC (0.44) | GRIK1GRIA2 | |
| SCHEMBL6374726 | 0.87 | CTSC (0.44) | GRIK1GRIA2 | |
| SCHEMBL1006317 | 0.87 | CTSC (0.44) | GRIK1GRIA2 | |
| SCHEMBL1768681 | 0.87 | CTSC (0.44) | GRIK1GRIA2 | |
| SCHEMBL16920345 | 0.87 | CTSC (0.44) | GRIK1GRIA2 | |
| SCHEMBL1006316 | 0.87 | CTSC (0.44) | GRIK1GRIA2 | |
| SCHEMBL5802417 | 0.87 | CTSC (0.44) | GRIK1GRIA2 | |
| SCHEMBL13585574 | 0.86 | EPHX2 (0.42) | GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | GRIK1 3651/4885GRIA2 3962/4885NAAA 1854/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | GRIK1 3651/4885GRIA2 3962/4885NAAA 1854/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | GRIK1 3808/4885GRIA2 4564/4885NAAA 1800/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | GRIK1 3651/4885GRIA2 3962/4885NAAA 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.